JorgeEnriqueMachado-‐Alba
88
48. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes
and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-‐
analysis. AmJGastroenterol
108
(1), 40-‐7(2013).
49. RodgersM, EpsteinD, Bojke L, YangH, CraigD, FonsecaT, et al. Etanercept, infliximab and
adalimumab for the treatment of psoriatic arthritis: a systematic review and economic
evaluation. HealthTechnol Assess
15
(10), 1-‐329(2011).
50. BurmesterGR, PanaccioneR, GordonKB,McIlraithMJ, LacerdaAP. Adalimumab: long-‐term
safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile
idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's
disease. AnnRheumDis
72
(4), 517-‐24(2013).
51. Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, NordströmDC, BlomM. Systematic
review and meta-‐analysis of the efficacy and safety of existing TNF blocking agents in
treatment of rheumatoidarthritis. PLoSOne
7
(1), e30275(2012).
52. Agarwal SK. Biologic agents in rheumatoid arthritis: an update for managed care
professionals. JManagCarePharm
17
(9Suppl B), S14-‐8(2011).
53. Simsek I. TNF inhibitors -‐ newandoldagents for rheumatoidarthritis. BullNYUHosp JtDis
68
(3), 204-‐10(2010).
54. Singh JA, Cameron DR. Summary of AHRQ's comparative effectiveness review of drug
therapy for rheumatoid arthritis (RA) in adults-‐-‐an update. J Manag Care Pharm
18
(4
SuppC), S1-‐18(2012).
55. Herrero-‐Beaumont G, Martínez CalatravaMJ, Castañeda S. Abataceptmechanismof action:
concordancewith its clinical profile. Reumatol Clin
8
(2), 78-‐83(2012).
56. Guyot P, Taylor P, ChristensenR, Pericleous L, Poncet C, LebmeierM, et al. Abataceptwith
methotrexateversus other biologic agents in treatment of patientswithactive rheumatoid
arthritis despite methotrexate: a network meta-‐analysis. Arthritis Res Ther
13
(6), R204
(2011).
57. Reichert JM.Marketed therapeuticantibodies compendium.MAbs
4
(3), 413-‐5(2012).
58. Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, et al. Dupilumab in
Persistent Asthma with Elevated Eosinophil Levels. N Engl J Med
368
(26), 2455-‐66
(2013).
59. LebreMC, JonckheereCL, KraanMC, vanKuijkAW, Bos JD, deRieM, et al. Expressionof IL-‐
20 in synoviumand lesional skin of patientswith psoriatic arthritis: differential response
toalefacept treatment. ArthritisResTher
14
(5), R200(2012).
60. SandbornWJ, Gasink C, Gao LL, BlankMA, Johanns J, Guzzo C, et al; CERTIFI Study Group.
Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J
Med
367
(16), 1519-‐28(2012).
61. Migone TS, Subramanian GM, Zhong J, Healey LM, Corey A, Devalaraja M, et al.
Raxibacumab for the treatment of inhalational anthrax. N Engl J Med
361
(2), 135-‐44
(2009).
62.Mazumdar S. Raxibacumab.MAbs
1
(6), 531-‐8(2009).
63. Ruf P, Kluge M, Jäger M, Burges A, Volovat C, Heiss MM, et al. Pharmacokinetics,
immunogenicity and bioactivity of the therapeutic antibody catumaxomab
intraperitoneally administered to cáncer patients. Br J Clin Pharmacol
69
(6), 617-‐25
(2010).
64. Xu L, Kohli N, Rennard R, Jiao Y, Razlog M, Zhang K, et al. Rapid optimization and
prototyping for therapeuticantibody-‐likemolecules.MAbs
5
(2), 237-‐54(2013)
65. SebastianM. Reviewof catumaxomab in the treatment ofmalignant ascites. CancerManag
Res
2
, 283-‐6(2010).
66. Seimetz D. Novel monoclonal antibodies for cancer treatment: the trifunctional antibody
catumaxomab (removab). J Cancer
2
, 309-‐16(2011).
67. Diaz JF, Cardenal R, Gomez-‐Manchero A, Sanchez-‐Gonzalez C. Safety and efficacy of
tirofiban as adjunctive therapy for patients with ST-‐elevation myocardial infarction: a
comparison versus placebo and abciximab. Cardiovasc Hematol Agents Med Chem
9
(3),
147-‐53(2011).
68. Michelson AD. Advances in antiplatelet therapy. Hematology Am Soc Hematol Educ
Program
2011
, 62-‐9(2011).
69. Klamová H, Poláková KM, Mužík J, Ráčil Z, Záčková D, Steinerová K, et al. Evaluation of 5-‐
year imatinib treatment of 458 patients with CP-‐CML in routine clinical practice and
prognostic impact of differentBCR-‐ABLcutoff levels. CancerMed
2
(2), 216-‐25(2013).
